Q3 Earnings Forecast for AC Immune Issued By Leerink Partnrs

Key Points

• AC Immune's Q3 2025 earnings per share estimates have been upgraded by Leerink Partners from ($0.25) to ($0.23), with the full-year earnings estimate at ($0.62) per share.
• The company reported ($0.25) earnings per share in its last quarterly earnings, missing analysts' expectations and generating revenue of $1.65 million.
• AC Immune has various ratings from analysts, with a consensus target price of $10.00 and a current average rating of "Hold."

AC Immune (NASDAQ:ACIU - Free Report) - Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of AC Immune in a note issued to investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($0.23) for the quarter, up from their previous forecast of ($0.25). The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune's Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at $0.31 EPS and FY2028 earnings at ($0.69) EPS.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.

A number of other equities research analysts have also weighed in on the company. BTIG Research reiterated a "buy" rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday, September 8th. Zacks Research upgraded AC Immune from a "strong sell" rating to a "hold" rating in a research report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of AC Immune in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AC Immune presently has an average rating of "Hold" and a consensus target price of $10.00.

AC Immune Stock Performance

Shares of ACIU stock opened at $3.52 on Thursday. The firm has a market cap of $353.44 million, a P/E ratio of -6.07 and a beta of 1.56. AC Immune has a fifty-two week low of $1.43 and a fifty-two week high of $3.99. The business's 50 day moving average price is $2.44 and its 200-day moving average price is $2.05.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Sei Investments Co. purchased a new position in shares of AC Immune in the second quarter worth $51,000. Banque Cantonale Vaudoise purchased a new stake in AC Immune during the first quarter valued at $50,000. Acadian Asset Management LLC increased its position in AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company's stock valued at $679,000 after acquiring an additional 172,796 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in AC Immune during the third quarter valued at $549,000. Finally, BVF Inc. IL increased its position in AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company's stock valued at $37,068,000 after acquiring an additional 300,000 shares during the last quarter. Hedge funds and other institutional investors own 51.36% of the company's stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.